(Melanoma) Is Relatlimab + Opdivo Effective?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
On February 13, 2023, Paolo Antonio Ascierto et al. (Melanoma, Cancer Immunotherapy) published in the Journal of Clinical Oncology the efficacy and safety results of relatlimab + nivolumab (Opdivo) in advanced melanoma patients previously treated with anti-PD-1/PD-L1 antibody therapy in the RELATIVITY-020 Phase 1/2a clinical trial.
The RELATIVITY-020 Phase 1/2a clinical trial enrolled advanced melanoma patients with prior anti-PD-1/PD-L1 antibody treatment (N=518), divided into a relatlimab monotherapy group and a relatlimab + Opdivo combination group. The primary endpoint was safety; secondary endpoints were objective response rate and progression-free survival.
Cohort D1 consisted of patients who had received one prior anti-PD-1/PD-L1 antibody treatment regimen (N=354); Cohort D2 consisted of patients who had received multiple prior anti-PD-1/PD-L1 antibody treatment regimens (N=164).
Trial results showed: the objective response rate was 12.0% for Cohort D1 and 9.2% for Cohort D2. Median duration of response for the secondary endpoint was: D1 — not reached / D2 — 12.8 months. Median progression-free survival was: D1 — 2.1 months / D2 — 3.2 months.
Regarding safety, Grade 3–4 adverse event rates were: D1 15.0% / D2 12.8%. Only one case of myocarditis was confirmed overall, and no deaths due to adverse events were recorded.
Based on the RELATIVITY-020 trial results, Paolo Antonio Ascierto et al. stated: In advanced melanoma patients previously treated with anti-PD-1/PD-L1 antibody therapy, relatlimab + Opdivo demonstrated durable antitumor activity and appeared to have manageable safety.
Source: https://ascopubs.org/doi/full/10.1200/JCO.22.02072
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4